kevindalby

 Originally published on prweb.com Dr.  Kevin Dalby , the principal investigator at the College of Pharmacy at the University of Texas at Austin, is one of six faculty members set to receive a recent grant to support ongoing, innovative cancer research. Recently, the Cancer Prevention and Research Institute awarded the six grants to UT faculty members as part of 73  grants they gave statewide that total more than $142 million. At the College of Pharmacy, Dr. Kevin Dalby is leading the investigation that will use the CPRIT award toward the Targeted Therapeutic Drug Discovery and Development Program. The goal of this particular program is to use new and integrated approaches to targeted molecular drug discovery. By doing this, it will increase the number of new compounds in the state of Texas that process needed qualities to eventually inhibit growth targets in tumors. Many researchers in the field of cancer have identified critically important targets related to cancer. Ho...

Originally published on   naturalsearcher.com Technology and advances in research proactively push forward to fight against a wide range of complex diseases called cancer. New drugs are being discovered, and innovative therapies are emerging every year, helping millions of cancer patients get back to their everyday healthy lives. However, many people are still pondering the question: will we ever get to the point where all cancers are cured? Kevin Dalby, UT Austin professor at the Department of Oncology in the College of Pharmacy, is an expert in cancer drug discovery and is studying cancer cell signaling mechanisms to develop targeted therapeutics. In the classroom at UT Austin, Kevin Dalby encourages his students to research to understand cancer better to create new treatments. Below, Dr. Dalby explains why it’s hard to say if all cancers will ever be treated successfully. "Due to the vast range of complicated and diverse factors that make up these diseases, finding a universal ...

  Originally published on   einnews.com Kevin Dalby, UT Austin professor comments on how cancer research clinical trials work and why they are so crucial for the future of cancer treatments. AUSTIN, TEXAS, UNITED STATES, April 20, 2021 /EINPresswire.com/ -- Kevin Dalby, UT Austin professor at the College of Pharmacy, knows the ins and outs of how cancer research trials work. He studies the mechanisms of cancer cell signaling to develop targeted therapeutics. Dalby’s efforts were recognized by the Cancer Prevention and Research Institute of Texas (CPRIT) and the National Institutes of Health, granting him nearly $5 million to support his research. Clinical trials are studies with the main focus of research surrounding a specific disease that involves people. These studies use and observe a new treatment approach to diseases such as a type or stage of cancer and compare it to the most effective treatment known at that time. They bring new waves of innovation to the medical world...